nach oben

Erschienen in:

01.04.2012 | Original Article

Teriparatide increases the maturation of circulating osteoblast precursors

verfasst von: P. D’Amelio, C. Tamone, F. Sassi, L. D’Amico, I. Roato, S. Patanè, M. Ravazzoli, L. Veneziano, R. Ferracini, G. P. Pescarmona, G. C. Isaia

Erschienen in: Osteoporosis International | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Summary

This study shows that teriparatide promotes the circulating osteoblast (OB) precursor degree of maturation in patients affected by postmenopausal osteoporosis.

Introduction

Anabolic treatment with teriparatide has proven effective for the therapy of postmenopausal osteoporosis and significantly reduces the risk of non-vertebral fragility fractures. The aim of this study was to investigate the effect of teriparatide on circulating OB precursors.

Methods

We evaluated by flow cytometry and real-time PCR the expression of OBs typical markers in peripheral blood mononuclear cells during treatment with teriparatide plus calcium and vitamin D, raloxifene plus calcium and vitamin D or calcium and vitamin D alone at various time points. Serum bone alkaline phosphatase and osteocalcin (OC) were measured as markers of bone turnover.

Results

Our results show that circulating OB precursors are more numerous and more immature in patients affected by fragility fractures than in osteoporotic patients without fractures. We also show that teriparatide treatment increases the expression of alkaline phosphatase and of OC in OB precursors; thus, it increases their degree of maturation.

Conclusions

We suggest that teriparatide acts as anabolic agents also by promoting the maturation of OB precursors.

Nur mit Berechtigung zugänglich

Eghbali-Fatourechi GZ, Lamsam J, Fraser D, Nagel D, Riggs BL, Khosla S (2005) Circulating osteoblast-lineage cells in humans. N Engl J Med 352:1959–1966PubMedCrossRef

Eghbali-Fatourechi GZ, Modder UI, Charatcharoenwitthaya N, Sanyal A, Undale AH, Clowes JA, Tarara JE, Khosla S (2007) Characterization of circulating osteoblast lineage cells in humans. Bone 40:1370–1377PubMedCrossRef

D’Amelio P, Cristofaro MA, Grimaldi A, Ravazzoli M, Pluviano F, Grosso E, Pescarmona GP, Isaia GC (2010) The role of circulating bone cell precursors in fracture healing. Calcif Tissue Int 86:463–469PubMedCrossRef

Kumagai K, Vasanji A, Drazba JA, Butler RS, Muschler GF (2008) Circulating cells with osteogenic potential are physiologically mobilized into the fracture healing site in the parabiotic mice model. J Orthop Res 26:165–175PubMedCrossRef

Pirro M, Leli C, Fabbriciani G, Manfredelli MR, Callarelli L, Bagaglia F, Scarponi AM, Mannarino E (2010) Association between circulating osteoprogenitor cell numbers and bone mineral density in postmenopausal osteoporosis. Osteoporos Int 21:297–306PubMedCrossRef

D’Amelio P, Roato I, D’Amico L, Veneziano L, Suman E, Sassi F, Bisignano G, Ferracini R, Gargiulo G, Castoldi F, Pescarmona GP, Isaia GC (2011) Bone and bone marrow pro-osteoclastogenic cytokines are up-regulated in osteoporosis fragility fractures. Osteoporos Int (in press)

Velasco J, Zarrabeitia MT, Prieto JR, Perez-Castrillon JL, Perez-Aguilar MD, Perez-Nunez MI, Sanudo C, Hernandez-Elena J, Calvo I, Ortiz F, Gonzalez-Macias J, Riancho JA (2010) Wnt pathway genes in osteoporosis and osteoarthritis: differential expression and genetic association study. Osteoporos Int 21:109–118PubMedCrossRef

Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB (2007) Effect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 146:326–339PubMed

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441PubMedCrossRef

10.

Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC (1999) Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104:439–446PubMedCrossRef

11.

Juppner H, Abou-Samra AB, Freeman M, Kong XF, Schipani E, Richards J, Kolakowski LF Jr, Hock J, Potts JT Jr, Kronenberg HM et al (1991) A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 254:1024–1026PubMedCrossRef

12.

Abou-Samra AB, Juppner H, Force T, Freeman MW, Kong XF, Schipani E, Urena P, Richards J, Bonventre JV, Potts JT Jr et al (1992) Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracellular free calcium. Proc Natl Acad Sci U S A 89:2732–2736PubMedCrossRef

13.

Bringhurst FR, Juppner H, Guo J, Urena P, Potts JT Jr, Kronenberg HM, Abou-Samra AB, Segre GV (1993) Cloned, stably expressed parathyroid hormone (PTH)/PTH-related peptide receptors activate multiple messenger signals and biological responses in LLC-PK1 kidney cells. Endocrinology 132:2090–2098PubMedCrossRef

14.

Schwindinger WF, Fredericks J, Watkins L, Robinson H, Bathon JM, Pines M, Suva LJ, Levine MA (1998) Coupling of the PTH/PTHrP receptor to multiple G-proteins. Direct demonstration of receptor activation of Gs, Gq/11, and Gi(1) by [alpha-32P]GTP-gamma-azidoanilide photoaffinity labeling. Endocr 8:201–209CrossRef

15.

Shinoda Y, Kawaguchi H, Higashikawa A, Hirata M, Miura T, Saito T, Nakamura K, Chung UI,Ogata N Mechanisms underlying catabolic and anabolic functions of parathyroid hormone on bone by combination of culture systems of mouse cells. J Cell Biochem 109:755–763

16.

Undale A, Srinivasan B, Drake M, McCready L, Atkinson E, Peterson J, Riggs BL, Amin S, Modder UI, Khosla S (2010) Circulating osteogenic cells: characterization and relationship to rates of bone loss in postmenopausal women. Bone 47:83–92PubMedCrossRef

17.

Kream BE, LaFrancis D, Petersen DN, Woody C, Clark S, Rowe DW, Lichtler A (1993) Parathyroid hormone represses alpha 1(I) collagen promoter activity in cultured calvariae from neonatal transgenic mice. Mol Endocrinol 7:399–408PubMedCrossRef

18.

Clohisy JC, Scott DK, Brakenhoff KD, Quinn CO, Partridge NC (1992) Parathyroid hormone induces c-fos and c-jun messenger RNA in rat osteoblastic cells. Mol Endocrinol 6:1834–1842PubMedCrossRef

19.

Civitelli R, Hruska KA, Jeffrey JJ, Kahn AJ, Avioli LV, Partridge NC (1989) Second messenger signaling in the regulation of collagenase production by osteogenic sarcoma cells. Endocrinology 124:2928–2934PubMedCrossRef

20.

Greenfield EM, Shaw SM, Gornik SA, Banks MA (1995) Adenyl cyclase and interleukin 6 are downstream effectors of parathyroid hormone resulting in stimulation of bone resorption. J Clin Invest 96:1238–1244PubMedCrossRef

21.

Miki Y, Suzuki T, Nagasaki S, Hata S, Akahira J, Sasano H (2009) Comparative effects of raloxifene, tamoxifen and estradiol on human osteoblasts in vitro: estrogen receptor dependent or independent pathways of raloxifene. J Steroid Biochem Mol Biol 113:281–289PubMedCrossRef

22.

Matsumori H, Hattori K, Ohgushi H, Dohi Y, Ueda Y, Shigematsu H, Satoh N, Yajima H, Takakura Y (2009) Raloxifene: its ossification-promoting effect on female mesenchymal stem cells. J Orthop Sci 14:640–645PubMedCrossRef

23.

D’Amelio P, Muratore M, Tinelli F, Tamone C, Cosentino L, Quarta E, Calcagnile F, Carlo Isaia G (2003) Effect of raloxifene and clodronate on bone density in postmenopausal osteoporotic women. Int J Tissue React 25:73–78PubMed

24.

D’Amelio P, Grimaldi A, Cristofaro MA, Ravazzoli M, Molinatti PA, Pescarmona GP, Isaia GC (2010) Alendronate reduces osteoclast precursors in osteoporosis. Osteoporos Int 21:1741–1750PubMedCrossRef

25.

D’Amelio P, Grimaldi A, Di Bella S, Tamone C, Brianza SZ, Ravazzoli MG, Bernabei P, Cristofaro MA, Pescarmona GP, Isaia G (2008) Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women. J Bone Miner Res 23:373–379PubMedCrossRef

26.

D’Amelio P, Grimaldi A, Pescarmona GP, Tamone C, Roato I, Isaia G (2005) Spontaneous osteoclast formation from peripheral blood mononuclear cells in postmenopausal osteoporosis. FASEB J 19:410–412PubMed

27.

Ballen K (2007) Targeting the stem cell niche: squeezing blood from bones. Bone Marrow Transplant 39:655–660PubMedCrossRef

28.

Gossl M, Modder UI, Atkinson EJ, Lerman A, Khosla S (2008) Osteocalcin expression by circulating endothelial progenitor cells in patients with coronary atherosclerosis. J Am Coll Cardiol 52:1314–1325PubMedCrossRef

29.

Chen P, Miller PD, Recker R, Resch H, Rana A, Pavo I, Sipos AA (2007) Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. J Bone Miner Res 22:1173–1180PubMedCrossRef

30.

Dobnig H, Turner RT (1995) Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 136:3632–3638PubMedCrossRef

31.

Nishida S, Yamaguchi A, Tanizawa T, Endo N, Mashiba T, Uchiyama Y, Suda T, Yoshiki S, Takahashi HE (1994) Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. Bone 15:717–723PubMedCrossRef

32.

Pettway GJ, Meganck JA, Koh AJ, Keller ET, Goldstein SA, McCauley LK (2008) Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation. Bone 42:806–818PubMedCrossRef

33.

Schmidt IU, Dobnig H, Turner RT (1995) Intermittent parathyroid hormone treatment increases osteoblast number, steady state messenger ribonucleic acid levels for osteocalcin, and bone formation in tibial metaphysis of hypophysectomized female rats. Endocrinology 136:5127–5134PubMedCrossRef

34.

Almeida M, Han L, Bellido T, Manolagas SC, Kousteni S (2005) Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by beta-catenin-dependent and -independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT. J Biol Chem 280:41342–41351PubMedCrossRef

35.

Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O’Brien CA, Manolagas SC, Jilka RL (2005) Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146:4577–4583PubMedCrossRef

36.

Rubin MR, Manavalan JS, Dempster DW, Shah J, Cremers S, Kousteni S, Zhou H, McMahon DJ, Kode A, Sliney J, Shane E, Silverberg SJ, Bilezikian JP (2011) Parathyroid hormone stimulates circulating osteogenic cells in hypoparathyroidism. J Clin Endocrinol Metab 96:176–186PubMedCrossRef

Titel: Teriparatide increases the maturation of circulating osteoblast precursors
verfasst von: P. D’Amelio
C. Tamone
F. Sassi
L. D’Amico
I. Roato
S. Patanè
M. Ravazzoli
L. Veneziano
R. Ferracini
G. P. Pescarmona
G. C. Isaia
Publikationsdatum: 01.04.2012
Verlag: Springer-Verlag
Erschienen in: Osteoporosis International / Ausgabe 4/2012
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-011-1666-2

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen.
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Teriparatide increases the maturation of circulating osteoblast precursors

Abstract

Summary

Introduction

Methods

Results

Conclusions

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Brustkrebs in der Vorgeschichte macht Gelenkersatz komplikationsträchtiger

Zwei neue Alternativen zu TNF-Inhibitoren bei axSpA

Update Orthopädie und Unfallchirurgie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Summary

Introduction

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2012

Omentin-1 exerts bone-sparing effect in ovariectomized mice

Multi-site bone ultrasound measurements in elderly women with and without previous hip fractures

Changes in bone mineral density and body composition during pregnancy and postpartum. A controlled cohort study

Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women

Genetic influence on bone mineral density in Korean twins and families: the healthy twin study

Prevalence of osteoporosis among cancer patients in Germany

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Brustkrebs in der Vorgeschichte macht Gelenkersatz komplikationsträchtiger

Zwei neue Alternativen zu TNF-Inhibitoren bei axSpA

Update Orthopädie und Unfallchirurgie